Bringing you the latest cutting-edge research and commentary in bioscience.

Cell & Gene Therapy Insights

Cell & Gene Therapy Insights

Spotlight Article

Progressing Bristol Myers Squibb’s clinical-stage pipeline of cellular cancer immunotherapies

Clinical development strategy, tools and trial designs

Stanley R Frankel

STANLEY R FRANKEL Following the acquisition of Celgene in 2019, Stan Frankel joined Bristol Myers Squibb as Senior Vice President, Cellular Therapy Development. Prior to his role at Bristol Myers Squibb, Stan served as Corporate Vice President, Head of Immuno-oncology, Clinical Research and Development, at Celgene for nearly five years. He oversaw the durvalumab alliance with Medimmune/AstraZeneca, the tislelizumab alliance with BeiGene, and the initial Celgene clinical development alliance with Juno Therapeutics. In addition to serving as co-chair and representative for vari-ous hematology/oncology development committees and leadership teams, Stan was the Head of the Cellular Ther-apy Center of Excellence and chaired the Celgene Protocol Review Committee. Earlier in his career, Stan led he-matology and oncology development programs in all phases of clinical development at Genta Therapeutics, Merck Research Labs, Roche, Micromet, and Amgen, and was instrumental in the approvals of Blincyto® and Zolinza®. Stan has internationally recognized clinical expertise across hematologic malignancies including acute promyelocytic leukemia (APL), acute lymphocytic leukemia (ALL), lymphoma and Waldenstrom’s macroglobulinemia. He has served as an academic investigator for the development of more than a dozen approved oncology drugs and has authored more than 80 peer-reviewed scientific papers. Previously, he had an academic practice in stem cell transplantation and hematologic malignancy clinical trials at Roswell Park Cancer Center, Georgetown University and the University of Maryland. Stan is a Diplomate of the American Board of Internal Medicine with subspecialty credentials in He-matology and Medical Oncology. He is also an Adjunct Associate Professor of Medicine at the Vagelos College of Physicians and Surgeons at Columbia University and is licensed to practice in New York. He is a Fellow and member of the American College of Physicians (ACP), and a member of the American Association for Cancer Research (AACR), American Society for Transplantation and Cellular Therapy (ASTCT), American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), European Hematology Association (EHA), and European Society for Medical Oncology (ESMO). Stan received his BA from Harvard College and his MD from Northwestern Univer-sity. He received his post-graduate training at Mount Sinai Hospital in New York, and Memorial Sloan-Kettering Cancer Center, where he was Chief Fellow.

DOI: 10.18609/cgti.2020.086
Citation: Cell & Gene Therapy Insights 2020; 6(5), 737–744
Open access
This content is restricted to registered users. Click here to Register or Login here.
Twitter IconVisit Our Blog